Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelike… Read more
Cara Therapeutic (CARA) - Total Assets
Latest total assets as of December 2024: $43.83 Million USD
Based on the latest financial reports, Cara Therapeutic (CARA) holds total assets worth $43.83 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cara Therapeutic - Total Assets Trend (2011–2024)
This chart illustrates how Cara Therapeutic’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cara Therapeutic - Asset Composition Analysis
Current Asset Composition (December 2024)
Cara Therapeutic's total assets of $43.83 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.5% |
| Accounts Receivable | $4.50 Million | 10.3% |
| Inventory | $900.00K | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Cara Therapeutic's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cara Therapeutic's current assets represent 100.0% of total assets in 2024, an increase from 42.7% in 2011.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2024, up from 38.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
Cara Therapeutic Competitors by Total Assets
Key competitors of Cara Therapeutic based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Cara Therapeutic - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cara Therapeutic generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cara Therapeutic is currently not profitable relative to its asset base.
Cara Therapeutic - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.03 | 4.54 | 4.07 |
| Quick Ratio | 10.81 | 4.43 | 4.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $39.85 Million | $ 90.57 Million | $ 100.07 Million |
Cara Therapeutic - Advanced Valuation Insights
This section examines the relationship between Cara Therapeutic's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -65.2% |
| Total Assets | $43.83 Million |
| Market Capitalization | $8.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cara Therapeutic's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cara Therapeutic's assets decreased by 65.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cara Therapeutic (2011–2024)
The table below shows the annual total assets of Cara Therapeutic from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.83 Million | -65.17% |
| 2023-12-31 | $125.84 Million | -30.94% |
| 2022-12-31 | $182.24 Million | -26.24% |
| 2021-12-31 | $247.06 Million | -8.89% |
| 2020-12-31 | $271.16 Million | +16.40% |
| 2019-12-31 | $232.96 Million | +22.08% |
| 2018-12-31 | $190.82 Million | +96.72% |
| 2017-12-31 | $97.00 Million | +51.98% |
| 2016-12-31 | $63.83 Million | -42.44% |
| 2015-12-31 | $110.90 Million | +98.26% |
| 2014-12-31 | $55.93 Million | +209.32% |
| 2013-12-31 | $18.08 Million | +226.58% |
| 2012-12-31 | $5.54 Million | -48.18% |
| 2011-12-31 | $10.69 Million | -- |